RNA and epigenetic editing: The new frontier in gene and cell therapy.
作者信息
Avila-Moreno Federico, Giangrande Paloma H
机构信息
Lung Diseases and Functional Epigenomics Laboratory (LUDIFE), Biomedicine Research Unit (UBIMED), Facultad de Estudios Superiores-Iztacala (FES-Iztacala), Universidad Nacional Autónoma de México (UNAM), México State, CP 54090, México; Research Unit, Instituto Nacional de Enfermedades Respiratorias (INER), Ismael Cosío Villegas, México City, CP 14080, México; Research Tower, Subdirección de Investigación Básica, Instituto Nacional de Cancerología (INCAN), México City, CP 14080, México.
Internal Medicine, University of Iowa, Iowa City, IA 52242, USA.
出版信息
Mol Ther. 2025 Feb 5;33(2):424-425. doi: 10.1016/j.ymthe.2025.01.017. Epub 2025 Jan 21.
Abstract
摘要
相似文献
1
RNA and epigenetic editing: The new frontier in gene and cell therapy.
Mol Ther. 2025 Feb 5;33(2):424-425. doi: 10.1016/j.ymthe.2025.01.017. Epub 2025 Jan 21.
2
Epigenetic editing and epi-drugs: a combination strategy to simultaneously target KDM4 as a novel anticancer approach.
Clin Epigenetics. 2025 Jun 19;17(1):105. doi: 10.1186/s13148-025-01913-0.
3
Precision scalpels for the epigenome: next-gen editing tools in targeted therapies.
Front Med (Lausanne). 2025 Jun 17;12:1613722. doi: 10.3389/fmed.2025.1613722. eCollection 2025.
4
Chemical Strategies to Modulate and Manipulate RNA Epigenetic Modifications.
Acc Chem Res. 2025 Jun 3;58(11):1727-1741. doi: 10.1021/acs.accounts.4c00844. Epub 2025 Mar 18.
5
RNA editing deficiency models differential immunogenicity of pancreatic α- and β-cells.
Mol Metab. 2025 Aug;98:102183. doi: 10.1016/j.molmet.2025.102183. Epub 2025 Jun 9.
6
A stochastic RNA editing process targets a select number of sites in individual glutamatergic motoneurons.
bioRxiv. 2025 Jul 1:2024.05.17.594696. doi: 10.1101/2024.05.17.594696.
7
rMATS-DVR: rMATS discovery of differential variants in RNA.
Bioinformatics. 2017 Jul 15;33(14):2216-2217. doi: 10.1093/bioinformatics/btx128.
8
Landscape of A-I RNA editing in mouse, pig, macaque, and human brains.
Nucleic Acids Res. 2025 Jun 6;53(11). doi: 10.1093/nar/gkaf534.
9
Cell-Penetrating Peptides and CRISPR-Cas9: A Combined Strategy for Human Genetic Disease Therapy.
Hum Gene Ther. 2024 Oct;35(19-20):781-797. doi: 10.1089/hum.2024.020.
10
Genetic architecture of RNA editing, splicing and gene expression in schizophrenia.
Hum Mol Genet. 2025 Feb 1;34(3):277-290. doi: 10.1093/hmg/ddae172.
本文引用的文献
1
Long-read RNA sequencing: A transformative technology for exploring transcriptome complexity in human diseases.
Mol Ther. 2025 Mar 5;33(3):883-894. doi: 10.1016/j.ymthe.2024.11.025. Epub 2024 Nov 19.
2
Preclinical evidence in the assembly of mammalian SWI/SNF complexes: Epigenetic insights and clinical perspectives in human lung disease therapy.
Mol Ther. 2024 Aug 7;32(8):2470-2488. doi: 10.1016/j.ymthe.2024.06.026. Epub 2024 Jun 22.
3
Decoding the specificity of mA RNA methylation and its implication in cancer therapy.
Mol Ther. 2024 Aug 7;32(8):2461-2469. doi: 10.1016/j.ymthe.2024.05.035. Epub 2024 May 24.
4
Decoding and overcoming T cell exhaustion: Epigenetic and transcriptional dynamics in CAR-T cells against solid tumors.
Mol Ther. 2024 Jun 5;32(6):1617-1627. doi: 10.1016/j.ymthe.2024.04.004. Epub 2024 Apr 6.
5
Metabolic reprogramming directed by super-enhancers in tumors: An emerging landscape.
Mol Ther. 2024 Mar 6;32(3):572-579. doi: 10.1016/j.ymthe.2024.02.003. Epub 2024 Feb 6.
6
m6A epitranscriptomic and epigenetic crosstalk in cardiac fibrosis.
Mol Ther. 2024 Apr 3;32(4):878-889. doi: 10.1016/j.ymthe.2024.01.037. Epub 2024 Feb 3.
7
RNA editing: Expanding the potential of RNA therapeutics.
Mol Ther. 2023 Jun 7;31(6):1533-1549. doi: 10.1016/j.ymthe.2023.01.005. Epub 2023 Jan 7.
8
The CRISPR craze.
Science. 2013 Aug 23;341(6148):833-6. doi: 10.1126/science.341.6148.833.
9
A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity.
Science. 2012 Aug 17;337(6096):816-21. doi: 10.1126/science.1225829. Epub 2012 Jun 28.
Zotero 插件